172 related articles for article (PubMed ID: 27777072)
1. Insights into ligand stimulation effects on gastro-intestinal stromal tumors signalling.
Bahlawane C; Schmitz M; Letellier E; Arumugam K; Nicot N; Nazarov PV; Haan S
Cell Signal; 2017 Jan; 29():138-149. PubMed ID: 27777072
[TBL] [Abstract][Full Text] [Related]
2. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
3. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
5. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
[TBL] [Abstract][Full Text] [Related]
6. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A
Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit.
Pelczar P; Zibat A; van Dop WA; Heijmans J; Bleckmann A; Gruber W; Nitzki F; Uhmann A; Guijarro MV; Hernando E; Dittmann K; Wienands J; Dressel R; Wojnowski L; Binder C; Taguchi T; Beissbarth T; Hogendoorn PC; Antonescu CR; Rubin BP; Schulz-Schaeffer W; Aberger F; van den Brink GR; Hahn H
Gastroenterology; 2013 Jan; 144(1):134-144.e6. PubMed ID: 23041331
[TBL] [Abstract][Full Text] [Related]
8. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
9. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.
Sápi Z; Füle T; Hajdu M; Matolcsy A; Moskovszky L; Márk A; Sebestyén A; Bodoky G
Diagn Mol Pathol; 2011 Mar; 20(1):22-33. PubMed ID: 21326036
[TBL] [Abstract][Full Text] [Related]
10. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.
Javidi-Sharifi N; Traer E; Martinez J; Gupta A; Taguchi T; Dunlap J; Heinrich MC; Corless CL; Rubin BP; Druker BJ; Tyner JW
Cancer Res; 2015 Mar; 75(5):880-91. PubMed ID: 25432174
[TBL] [Abstract][Full Text] [Related]
12. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
[TBL] [Abstract][Full Text] [Related]
13. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.
Ran L; Sirota I; Cao Z; Murphy D; Chen Y; Shukla S; Xie Y; Kaufmann MC; Gao D; Zhu S; Rossi F; Wongvipat J; Taguchi T; Tap WD; Mellinghoff IK; Besmer P; Antonescu CR; Chen Y; Chi P
Cancer Discov; 2015 Mar; 5(3):304-15. PubMed ID: 25572173
[TBL] [Abstract][Full Text] [Related]
16. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
17. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
19. Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA.
de Raedt T; Cools J; Debiec-Rychter M; Brems H; Mentens N; Sciot R; Himpens J; de Wever I; Schöffski P; Marynen P; Legius E
Gastroenterology; 2006 Dec; 131(6):1907-12. PubMed ID: 17087943
[TBL] [Abstract][Full Text] [Related]
20. Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.
Bosbach B; Rossi F; Yozgat Y; Loo J; Zhang JQ; Berrozpe G; Warpinski K; Ehlers I; Veach D; Kwok A; Manova K; Antonescu CR; DeMatteo RP; Besmer P
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):E8448-E8457. PubMed ID: 28923937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]